Pharmacyclics Company Profile (NASDAQ:PCYC)

About Pharmacyclics (NASDAQ:PCYC)

Pharmacyclics logoPharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:PCYC
  • CUSIP: 71693310
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $256.91
  • 200 Day Moving Avg: $195.29
  • 52 Week Range: $85.50 - $261.68
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 48.97
  • P/E Growth: 0.00
Misc:
  • Average Volume: 1.33 million shs.
 

Frequently Asked Questions for Pharmacyclics (NASDAQ:PCYC)

What is Pharmacyclics' stock symbol?

Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."

How were Pharmacyclics' earnings last quarter?

Pharmacyclics, Inc. (NASDAQ:PCYC) issued its quarterly earnings results on Friday, May, 1st. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The company earned $206 million during the quarter, compared to the consensus estimate of $226.27 million. View Pharmacyclics' Earnings History.

Who are some of Pharmacyclics' key competitors?

How do I buy Pharmacyclics stock?

Shares of Pharmacyclics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pharmacyclics stock cost?

One share of Pharmacyclics stock can currently be purchased for approximately $257.10.

Analyst Ratings

Consensus Ratings for Pharmacyclics (NASDAQ:PCYC) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Pharmacyclics (NASDAQ:PCYC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/29/2015BTIG ResearchReiterated RatingNeutralN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Pharmacyclics (NASDAQ:PCYC)
Earnings by Quarter for Pharmacyclics (NASDAQ:PCYC)
Earnings History by Quarter for Pharmacyclics (NASDAQ:PCYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2015Q115$0.11$0.13$226.27 million$206.00 millionViewN/AView Earnings Details
2/18/2015Q414$0.76$0.96$267.50 million$290.00 millionViewN/AView Earnings Details
11/4/2014Q314$0.37$0.69$201.50 million$207.10 millionViewN/AView Earnings Details
7/31/2014Q214($0.23)($0.26)$95.88 million$113.00 millionViewN/AView Earnings Details
5/2/2014Q114$0.17$0.40$105.38 million$119.40 millionViewN/AView Earnings Details
2/20/2014Q413$0.67$0.95$85.69 million$123.60 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.07)$0.26$52.00 million$54.70 millionViewN/AView Earnings Details
5/1/2013Q3 2013($0.03)($0.40)$2.84 millionViewN/AView Earnings Details
2/14/2013Q2 2013$0.29$0.62$45.74 million$57.96 millionViewN/AView Earnings Details
11/5/2012Q113$0.75$1.14$87.64 million$102.70 millionViewN/AView Earnings Details
9/5/2012Q412($0.27)($0.22)$3.49 million$2.10 millionViewN/AView Earnings Details
5/10/2012($0.20)($0.14)ViewN/AView Earnings Details
2/9/2012($0.18)$0.82ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pharmacyclics (NASDAQ:PCYC)
Current Year EPS Consensus Estimate: $0.73 EPS
Next Year EPS Consensus Estimate: $5.25 EPS

Dividends

Dividend History for Pharmacyclics (NASDAQ:PCYC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Pharmacyclics (NASDAQ:PCYC)
Insider Trades by Quarter for Pharmacyclics (NASDAQ:PCYC)
Insider Trades by Quarter for Pharmacyclics (NASDAQ:PCYC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/13/2015Manmeet Singh SoniCFOSell27,514$254.24$6,995,159.36View SEC Filing  
3/12/2015Heow TanInsiderSell1,000$254.51$254,510.00View SEC Filing  
11/12/2014Maky ZanganehCOOSell30,482$134.69$4,105,620.58View SEC Filing  
11/10/2014Maky ZanganehCOOSell23,000$133.83$3,078,090.00View SEC Filing  
11/10/2014Richard B LoveGeneral CounselSell1,500$133.87$200,805.00View SEC Filing  
11/7/2014Maky ZanganehCOOSell1,551$135.01$209,400.51View SEC Filing  
11/7/2014Maria FardisInsiderSell5,000$134.50$672,500.00View SEC Filing  
9/4/2014Maky ZanganehCOOSell12,000$121.75$1,461,000.00View SEC Filing  
8/27/2014Richard B LoveGeneral CounselSell1,500$124.00$186,000.00View SEC Filing  
8/13/2014Heow TanInsiderSell10,000$123.58$1,235,800.00View SEC Filing  
8/7/2014Jesse McgreivyInsiderSell34,062$120.92$4,118,777.04View SEC Filing  
3/5/2014Boultbee Paula SjovallEVPSell20,000$138.22$2,764,400.00View SEC Filing  
3/5/2014Gregory HemmiVPSell15,000$140.00$2,100,000.00View SEC Filing  
3/5/2014Jesse McgreivyInsiderSell6,563$139.66$916,588.58View SEC Filing  
3/4/2014Betty ChangVPSell17,500$137.97$2,414,475.00View SEC Filing  
2/27/2014Den Broek Richard VanDirectorSell78,835$146.63$11,559,576.05View SEC Filing  
12/19/2013Heow TanInsiderSell5,000$100.87$504,350.00View SEC Filing  
12/18/2013Gregory HemmiVPSell20,000$100.52$2,010,400.00View SEC Filing  
12/16/2013Rainer ErdtmannVPSell54,000$107.77$5,819,580.00View SEC Filing  
6/6/2013Scott T ShearerVPSell18,750$85.17$1,596,937.50View SEC Filing  
5/31/2013Heow TanInsiderSell5,237$91.84$480,966.08View SEC Filing  
5/31/2013Jesse McgreivyVPSell14,479$91.13$1,319,471.27View SEC Filing  
2/5/2013David J LouryInsiderSell20,000$70.58$1,411,600.00View SEC Filing  
12/28/2012Den Broek Richard VanDirectorSell30,285$57.99$1,756,227.15View SEC Filing  
12/27/2012Gregory HemmiVPSell13,000$59.20$769,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pharmacyclics (NASDAQ:PCYC)
Latest Headlines for Pharmacyclics (NASDAQ:PCYC)
Source:
DateHeadline
bizjournals.com logoCan a 72-year-old, surf-loving Scientologist score again with this med device startup?
www.bizjournals.com - April 7 at 11:50 AM
News IconUPDATE 1-TG Therapeutics' leukemia drug clears hurdle in key study
www.businessinsider.com - March 7 at 9:50 AM
bizjournals.com logoThese drug and medical device companies made the most payments to Chicago hospitals
www.bizjournals.com - March 2 at 8:44 AM
bizjournals.com logoHere’s where a Pinellas billionaire and top donor to Church of Scientology is putting his investment dollars
www.bizjournals.com - March 2 at 8:44 AM
seekingalpha.com logoFormer Pharmacyclics execs take 17% stake in Pulse Bio; shares up 33%
seekingalpha.com - February 10 at 9:47 AM
zacks.com logoAbbvie (ABBV) Imbruvica Approved in Lymphoma Indication
www.zacks.com - January 20 at 7:59 PM
streetinsider.com logoAbbVie (ABBV) Announces FDA Approval for IMBRUVICA to Treat Specifically Indicated for R/R MZL - StreetInsider.com
www.streetinsider.com - January 19 at 11:50 PM
streetinsider.com logoAbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD
www.streetinsider.com - December 7 at 7:04 PM
finance.yahoo.com logoLate-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients …
finance.yahoo.com - December 6 at 11:54 PM
streetinsider.com logoAbbVie (ABBV) Updates on Five-Year IMBRUVICA Data in CLL/SLL; Strong CR/PR Results Noted - StreetInsider.com
www.streetinsider.com - December 6 at 6:52 PM
streetinsider.com logoAbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD - StreetInsider.com
www.streetinsider.com - December 6 at 6:52 PM
prnewswire.com logoIMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and - PR Newswire (press release)
www.prnewswire.com - December 5 at 9:48 AM
businesswire.com logoData at ASH 2016 Show Strong, Lasting Efficacy of Imbruvica® (ibrutinib) Through Five Years of Treatment for ... - Business Wire (press release)
www.businesswire.com - December 5 at 9:48 AM
streetinsider.com logoJanssen Announces Follow-up Data on IMBRUVICA Phase 1b/2 as ... - StreetInsider.com
www.streetinsider.com - December 5 at 9:48 AM
seekingalpha.com logoGilead Sciences Closes Above Its Downward Channel, Are Future Gains To Follow? - Seeking Alpha
seekingalpha.com - November 15 at 10:29 AM
finance.yahoo.com logoAbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma
finance.yahoo.com - September 26 at 6:47 PM
prnewswire.com logoAbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for - PR Newswire (press release)
www.prnewswire.com - September 26 at 11:30 AM
finance.yahoo.com logoSeveral Companies Reach 52-Week Highs - Yahoo Finance
finance.yahoo.com - September 21 at 6:19 PM
benzinga.com logoGoldman Sachs Talks Pfizer's Acquisition Deal Of Medivation - Benzinga
www.benzinga.com - August 24 at 9:50 AM
seekingalpha.com logoACADIA Pharmaceuticals Could Be Acquired - Seeking Alpha
seekingalpha.com - June 7 at 9:30 AM
streetinsider.com logoAbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL - StreetInsider.com
www.streetinsider.com - June 6 at 10:26 AM
streetinsider.com logoAbbVie (ABBV) Receives EC Approval of IMBRUVICA as CLL Treatment - StreetInsider.com
www.streetinsider.com - May 31 at 7:01 PM
prnewswire.com logoEuropean Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic ... - PR Newswire (press release)
www.prnewswire.com - May 31 at 6:38 AM
finance.yahoo.com logoMedivation Is for Sale: How Much Should It Get?
finance.yahoo.com - May 13 at 6:07 PM
forbes.com logoTax Savvy Execs Work For $1, Get Paid Millions As Capital Gain
www.forbes.com - May 2 at 8:43 AM

Social

Chart

Pharmacyclics (PCYC) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff